D-ribose
Also known as: D ribose
A pentose sugar with small cardiac feasibility studies, a glucose-lowering caution and exposure-dependent food safety assessments.
D-ribose is a five-carbon sugar studied in energy metabolism. A small heart-failure trial reported changes in some diastolic measures and quality of life, not proof of longer survival or routine energy enhancement. Oral ribose can lower blood glucose; food safety assessments do not establish an effective supplement dose.1, 2, 3
- The 2003 cardiac feasibility trial included 15 people and three-week treatment periods.1
- EFSA reviewed human observations of transient glucose reductions, including uncertainty about susceptible people.2
- A later 2018 EFSA statement accepted revised proposed food uses; the initial and revised exposure assessments must be read together.2, 3
What is D-ribose?
Ribose has a biochemical connection to nucleotide and ATP metabolism. The novel-food assessment describes a manufactured D-ribose ingredient, including production by fermentation. Being part of normal metabolism does not mean that additional grams improve function in every person.2, 1
Where it comes from
Natural sources
- A pentose involved in endogenous nucleotide metabolism.
How it's made
The assessed novel-food ingredient was manufactured through a fermentation process; it is not simply an ordinary mixed-food serving.
What it does in products
Benefits
A cardiac signal remains preliminary
limited evidenceA short feasibility result is not an established heart-failure treatment.1
The randomized crossover trial studied people with coronary disease and heart failure, not healthy people seeking more energy. Some filling-related measures and quality of life improved; the sample and duration cannot establish hospitalization or mortality benefits. Two authors were affiliated with Bioenergy, Inc.
Evidence scope and limitations
Isolated oral D-ribose, one cardiac feasibility trial and the original plus revised 2018 EFSA novel-food assessments; not a systematic efficacy review for every fatigue or athletic indication.
- Small, short cardiac findings do not transfer to healthy users, different cardiac diagnoses or long-term clinical outcomes.
- A safety benchmark is not an effective dose; the later food assessment explicitly cautioned about extra supplement exposure.
- The medication caution is an editorial inference from the observed glucose effect, not evidence that a specific drug interaction magnitude was measured.
Evidence last checked: 2026-10-23
Side effects & safety
Safety considerations
- Glucose-lowering medicines and a history of low blood sugar warrant professional assessment; this is a precaution from the observed glucose effect, not a quantified interaction trial.
- Not for: Do not infer that a short study in cardiac patients establishes safety for high-dose use in pregnancy, childhood or other unstudied groups.
- Not for: Combining fortified foods and supplements can exceed the exposure used in the revised food assessment.
Amounts studied & product use
These figures describe research or common product use, not a personal dose or treatment recommendation.
In supplement studies and products
The cardiac experiment used 5 g per dose three times daily with meals for three weeks in each treatment period. That is a study regimen, not a recommendation. EFSA's 36 mg/kg body weight/day benchmark concerns safety assessment of combined exposure, not an energy target or a personalized safe maximum.
Regulatory status
- The EFSA documents are European safety assessments, not U.S. FDA drug approvals. FDA's supplement framework does not preapprove clinical effectiveness. Neither a novel-food assessment nor supplement labeling demonstrates an approved heart-failure treatment.
Why the two EFSA conclusions differ
The first assessment found the applicant's proposed food exposures too high for its acceptable-intake benchmark. After the proposed uses and levels changed, the later statement concluded that the revised conditions were safe, while flagging additional exposure from supplements.
The apparent reversal was about the exposure scenario, not proof that an ingredient changed from dangerous to therapeutic. Keep grams used in a clinical experiment separate from a population safety benchmark; neither number answers whether someone will feel more energetic.
2, 3, 1Frequently asked questions
The bottom line
Read the small cardiac study and the glucose/exposure cautions together, rather than turning ATP language into a treatment promise.
References
- Omran H, Illien S, MacCarter D, St. Cyr J, Lüderitz B. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: a prospective feasibility study. European Journal of Heart Failure (2003) · randomized trial · PMID 14607200; DOI 10.1016/S1388-9842(03)00060-6; original article and publisher PDF methods checked
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Safety of d-ribose as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal (2018) · safety assessment · DOI 10.2903/j.efsa.2018.5265; final opinion adopted April 18, 2018; human glucose effects and original proposed-use limitations checked
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Statement on the safety of d-ribose. EFSA Journal (2018) · safety assessment · DOI 10.2903/j.efsa.2018.5485; final statement adopted October 24, published December 13, 2018; revised exposure conditions, not an efficacy assessment
- Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration · government guidance · Undated agency resource; current premarket-approval, claims and professional-consultation framework checked October 23, 2026
Revision history
- Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.